Corcept Therapeutics Inc. (NASDAQ:CORT) shares were up 4.6% on Tuesday . The company traded as high as $6.12 and last traded at $6.10, with a volume of 586,750 shares changing hands. The stock had previously closed at $5.83.

A number of research analysts have weighed in on CORT shares. FBR & Co reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research note on Saturday, June 4th. Zacks Investment Research raised shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Tuesday, July 12th.

The firm’s 50-day moving average price is $5.72 and its 200-day moving average price is $4.88. The stock has a market cap of $669.09 million and a P/E ratio of 672.22.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, August 2nd. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. The firm earned $19.70 million during the quarter, compared to analysts’ expectations of $18.36 million. On average, equities research analysts predict that Corcept Therapeutics Inc. will post $0.06 EPS for the current fiscal year.

An institutional investor recently raised its position in Corcept Therapeutics stock. Globeflex Capital L P boosted its stake in Corcept Therapeutics Inc. (NASDAQ:CORT) by 164.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 244,301 shares of the company’s stock after buying an additional 151,869 shares during the period. Globeflex Capital L P owned about 0.22% of Corcept Therapeutics worth $1,217,000 at the end of the most recent reporting period.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.